Program at a Glance

ISCT NA 2023

CONCURRENT SESSIONS

60-minute sessions.  Formal presentations with Q&A.  

BALANCING RISKS AND OUTCOMES: GENE THERAPY VS. TRANSPLANT

  • Chair: Jaap Boelens, MD, PhD, Pediatric-Oncologist, Chief, Transplantation and Cellular Therapies, MSKCC
  • Speakers: 
    • Troy Lund, MD, PhD, Associate Professor, Department of Pediatrics, University of Minnesota Medical School
    • Akshay Sharma, MBBS, Assistant Member, St. Jude Faculty, St. Jude Children's Research Hospital
    • Michael Keller, MD, Director, Translational Research Laboratory - CETI, Children's National

VARIABLES IMPACTING OUTCOMES AFTER IEC

  • Chair: Kevin Curran, MD, Pediatric Hematologist-Oncologist, MSKCC
  • Speakers:
    • Sarah Nikiforow, MD, PhD, Asst Professor, Stem Cell Transplantation Program, Asst Medical Director, Cell Manipulation Core Facility, Dana Farber Cancer Institute
    • Regina Myers, MD, Divisions of Oncology, Cellular Therapy and Transplantation, Children's Hospital of Philadelphia
    • Kevin Curran, MD, Pediatric Hematologist-Oncologist, MSKCC

SUCCESS AND CHALLENGES WITH ALLO CARs

  • Chair: Jason Bock, PhD, Founder and CEO, CTMC
  • Speakers:
    • Charles Mooney, MBA, MS, MT(ASCP)SBB, Vice-President, Research & BioDevelopment, Oklahoma Blood Institute and BioSharing Network
    • Sarah Nikiforow, MD, PhD, Asst Professor, Stem Cell Transplantation Program, Asst. Medical Director, Cell Manipulation Core Facility, Dana Farber Cancer Institute
    • Lou Bartolo, DNP, MSN, RN, Senior Regulatory Affairs Associate, NMDP

CURRENT VS. FUTURE: A SUSTAINABLE BUSINESS MODEL FOR COLLECTION FACILITIES

  • Chair: Joseph Schwartz, MD, MPH, Director, Transfusion Medicine, Moffitt Cancer Center and Research Institute
  • Speakers: 
    • Yara Park, MD, Director, Residency Training Program, Professor, UNC School of Medicine, Pathology and Lab Medicine
    • Hope Guidry-Groves, Senior Director, Network Partners at NMDP
    • Lee Buckler, JD, Senior VP of Advanced Therapies, Blood Centers of America

EVENTS IN THE CTL - THE QUADRUPLE C - CRYOPRESERVATION, CITATIONS, CONTAMINATION AND CAP

  • Chair and Speaker: Joseph Schwartz, MD, MPH, Director, Transfusion Medicine, Moffitt Cancer Center and Research Institute
  • Speakers:
    • Cheryl Cox, MT(ASCP), CSSMBB, Director, Cell Therapy Operations, Moffitt Cancer Center
    • Jelena Holovati, PhD, Associate Professor and Director, Department of Laboratory Medicine and Pathology, Laboratory Director, Stem Cell Manufacturing, Canadian Blood Services, University of Alberta

LESSONS LEARNED FROM GLOBAL EMERGING CELL THERAPY PROGRAMS

  • Chair and Speaker: Prakash Satwani, MD, Director of Pediatric Cellular Therapy Program, Columbia University Irving Medical Center
  • Speaker:
    • Samuel Campanelli Freitas Coutu, PhD, Coordinator, Cell Therapy Laboratory, Fundação Pró-Sangue Hemocentro de São Paulo and Children's National
    • Jaap Boelens, MD, PhD, Pediatric-Oncologist, Chief, Transplantation and Cellular Therapies, MSKCC

OPTIMIZING TOXICITY AND RELAPSE CONTROL AFTER HCT

  • Chair: Jaap Boelens, MD, PhD, Pediatric-Oncologist, Chief, Transplantation and Cellular Therapies, MSKCC
  • Speakers: 
    • Alex Lucas, MD, MSc, Pediatric Hematologist-Oncologist, Memorial Sloan Kettering Cancer Center
    • Shabi Soheili, PhD, R&D Director, SmartImmune
    • Andromachi Scaradavou, MD, Pediatric Hematologist-Oncologist, Memorial Sloan Kettering Cancer Center

THE 4Ps OF THERAPIES: PATIENTS, PAYORS, PROVIDERS AND POLICY MAKERS

  • Chair: Bambi Grilley, B.S., RPh, RAC, CIP CCRC, CCRP, Director - Clinical Research and Early Product Development, Baylor College of Medicine
  • Speakers:
    • Akshay Sharma, MBBS, Assistant Member, St. Jude Faculty, St. Jude Children's Research Hospital
    • Ashley Hume, Senior Vice President, Strategic Growth & Client Engagement, Emerging Therapy Solutions
    • Lakiea Bailey, PhD, Sickle Cell Consortium

CELL THERAPIES FOR AUTOIMMUNE DISEASES

  • Chair: Anthony Ting, PhD, Principal, BRL C&GT Consulting, LLC
  • Speakers:
    • Gary S. Gilkeson, MD, Distinguished University Professor, Associate Dean for Faculty Affairs and Faculty Development, Medical University of South Carolina
    • Simrit Parmar , MD, Associate Professor MD Anderson Cancer Center, Founder, Cellenkos
    • Natalie Belmonte, PhD, SVP Research & Translation, Quell Therapeutics, 

GAME-CHANGERS FOR OPTIMIZING OPERATIONS AT CELL THERAPY PROCESSING FACILITIES 

  • Chair: Elena Maryamchik, MD, MBA, Director of Cell Therapy Laboratory, MSKCC
  • Speaker: 
    • Yongping Wang, MD, PhD, Director of Cell and Gene Therapy Lab, The Children's Hospital of Philadelphia
    • Emily Hopewell, PhD, Assistant Professor of Clinical Medical and Molecular Genetics, Director, Cell and Gene Therapy Manufacturing, Chief Operations Officer, Brown Center for Immunotherapy, Indiana University
    • Karen Moniz, Technical Director, ICCBBA

RELEASE ASSAY QUALIFICATION VALIDATION 101

  • Chair: Ashley Krull, PhD, Associate Director, Cell Therapy Manufacturing and Engineering, The Ohio State University
  • Speaker:
    • Melba Marie Page, PhD, Analytical Laboratory (QC) Manager, Moffitt Cancer Center
    • Scott Jones, PhD, Senior Vice President & CSO, BioBridge Global
    • Brigitte Senechal, PhD, Head of QC Analytics for Qualification, Validation and Clinical Release, MSKCC

ABCs OF POINT OF CARE MANUFACTURING OF IEC

  • Chair: Olive J Sturtevant, MHP, MT(ASCP)SBB,SLS, CQA(ASQ), Senior Administrative Director of Connell & O'Reilly Families, Cell Manipulation Core Facility, Dana Farber Cancer Institute
  • Speakers: 
    • Don Siegel, MD, PhD, Professor, Pathology & Laboratory Medicine, University of Pennsylvania
    • Tim Wiltshire, PhD, Section Director-IMPACT Lab, Mayo Clinic Rochester
    • Sarah Nikiforow, MD, PhD, Asst Professor, Stem Cell Transplantation Program, Asst. Medical Director, Cell Manipulation Core Facility, Technical Director, Immune Effector Program Dana-Farber Cancer Institute

POINT OF CARE (POC) NUTS AND BOLTS: QC TESTING

  • Chair: Rupa Pike, PhD, Senior Director of Technical Affairs, Catalent Pharma Solutions
  • Speakers: 
    • Larry Bellot, PhD, Scientific Advisor, Charles River Laboratories
    • Anushree Anil Datar, MSc, Cell Therapy Lab Team Lead, Children's National
    • Stephanie Mgebroff, MSc, Director, GMP Quality Control, Seattle Children's Research Institute

RELEVANT NON-HUMAN MODELS: PROGRESS AND PROCESS

  • Chair: Bambi Grilley, B.S., RPh, RAC, CIP CCRC, CCRP, Director - Clinical Research and Early Product Development, Baylor College of Medicine
  • Speaker:
    • Matthew Hewitt, PhD, Vice President, Technical Officer CGT & Biologics, Charles River Laboratories
    • Hajime Hiraragi, PhD, MBA, Vice President, Pathology & Nonclinical Development, Lyell Immunopharma
    • Hang Lin, PhD, Associate Professor, Department of Orthopaedic Surgery & Bioengineering, University of Pittsburgh

MSC POTENCY AND MECHANISMS OF ACTION: STATE OF THE ART

  • Chair: James Ankrum, BSE, MPhil, PhD, Associate Professor of Biomedical Engineering, University of Iowa 
  • Speakers:
    • Sing Wan Wong, PhD, Assistant Professor, Colorado State University
    • Lorena Braid, PhD, Professor and Canada Research Chair in Mesenchymal Stromal Cell Biology, Simon Fraser University
    • Giacomo Lanzoni, PhD, Assistant Professor, Diabetes Research Institute, University of Miami

TiLs: Yesterday's news or the Next Big Thing in Cell Therapy

  • Chair: Jason Bock, PhD, Founder and CEO, CTMC 
  • Speakers:
    • Madan Jagasia, MD, MS, CEO, Obsidian Therapeutics
    • Elliot Reno, BSE, Senior Medical Science Liaison, Iovance Biotherapeutics
    • Qasim Rizvi, MBChB, MBA, CEO, KSQ Therapeutics

EXTRACELLULAR VESICLES: BENCH TO BEDSIDE

  • Chair and Speaker: Elani Wiest, PhD, Associate Staff Scientist - Process Development, Center for Regenerative Biotherapeutics
  • Speakers:
    • Bruna Corrandeti, PhD, Assistant Professor, Baylor College of Medicine
    • Olesia Gololobova, PhD, Witwer Lab, Johns Hopkins University
    • Honami Naora, PhD, Department of Molecular and Cellular Oncology, MD Anderson Cancer Center

BRIDGING THE SKILLS GAP IN CGT MANUFACTURING: DEVELOPMENT PATHWAYS FOR EARLY STAGE PROFESSIONALS

  • Chair and Speaker: Shalu Suri, PhD, CMAT, Georgia Institute of Technology
  • Panelists:
    • Patrick Hanley, PhD, Children's National Hospital
    • Matthew Hewitt, PhD, Charles River Laboratory
    • Kevin Bosse, PhD, RAC-US, CABP(H), Nationwide Children's Hospital

ROUNDTABLE SESSIONS

60 minute sessions.  No presentations.
Interactive discussions to debate, deliberate, and drive consensus

FIELDING CMC QUESTIONS FROM THE FDA: IMPROVE YOUR COMMUNICATION STRATEGY AND RESPONSES

  • Moderator: J. Wade Atkins, MS, MT(ASCP) SBB, CQA (ASQ), QA Specialist, NIH Clinical Center Department of Transfusion Medicine (DTM)
  • Panelists:
    • Olive J Sturtevant, MHP, MT(ASCP)SBB,SLS, CQA(ASQ), Senior Administrative Director of Connell & O'Reilly Families, Cell Manipulation Core Facility, Dana Farber Cancer Institute
    • Patrick Hanley, PhD, Chief and Director, Cellular Therapy Program, Children's National
    • Kevin Bosse, PhD, RAC-US, CABP(H), Director, Office of Research Regulatory Affairs, Nationwide Children’s Hospital

WHAT IS THE FUTURE OF VIRUS-SPECIFIC T CELLS?

  • Co-Moderators: 
    • Patrick Hanley, PhD, Chief and Director, Cellular Therapy Program, Children's National
      Michael Keller, MD, Director, Translational Research Laboratory - CETI
  • Panelists:
    • Michael Keller, MD, Director, Translational Research Laboratory - CETI
    • Kevin Curran, MD, Pediatric Hematologist-Oncologist, MSKCC
    • Allyson Flower, MD, Assistant Professor of Pediatrics, Division of Pediatric Hematology Oncology, New York Medical College

WHAT IS THE FUTURE OF MSCS? NAVIGATING THE PATH FORWARD

  • Moderator: Daniel J. Weiss, MD, PhD, Professor of Medicine, University of Vermont
  • Panelists:
    • Charles Cox, MD, Children’s Fund Distinguished Professor; Director of the Pediatric Trauma Program at Children’s Memorial Hermann Hospital, Department of Pediatric Surgery; Professor, Center for Stem Cell & Regenerative Medicine, University of Texas
    • Jacques Galipeau, MD FRCP(C), Don and Marilyn Anderson Professor in Oncology, Associate Dean for Therapeutics Development, University of Wisconsin in Madison
    • Kilian Kelly, Chief Executive Officer and Managing Director, Cynata
    • Raghavan Chinnadurai, PhD, Assistant Professor Of Oncology Department of Biomedical Sciences Mercer University School Of Medicine

TRANSFORMATIVE TRENDS: NAVIGATING THE EVOLUTION OF STEM CELL PROCESSING LABS

  • Moderator: Joseph Schwartz, MD, MPH, Director, Transfusion Medicine, Moffitt Cancer Center and Research Institute
  • Panelists:
    • Kathryn Bushnell, MSHS, MLS(ASCP), CABP(AABB), Cell Therapy Lab Manager, Children's National
    • Wesley McKinney, Laboratory Director of the Cell Processing Facility, Center for Cell and Gene Therapy, Baylor College of Medicine
    • Julie Annis, MLS(ASCP)CM, TCT Laboratory Manager, Children’s Hospital Los Angeles

THRIVING WORKFORCE, THRIVING LABS: STRATEGIES FOR BUILDING YOUR CGT TEAM

  • Moderator: Elena Maryamchik, MD, MBA, Director of Cell Therapy Laboratory, MSKCC
  • Panelists:
    • Jelena Holovati, PhD, University of Alberta/Canadian Blood Services
    • Lauren McVoy, MD, PhD, Vice Chair for Clinical Integration and the leader of education at the Department of Pathology and Laboratory Medicine at MSKCC
    • Ashley Krull, PhD, Associate Director, Cell Therapy Manufacturing and Engineering, The Ohio State University
    • Margaret DiGuardo, MD, Pathologist/Fellow Physicians, Mayo Clinic IMPACT

STRIKING SPEED AND COMPLIANCE BALANCE IN CELL THERAPY PATIENT ACCESS

  • Chair: Josh Ludwig, Global Director Commercial Operations ScaleReady
  • Speakers:
    • Brent Chesson PhD MPH Principal Scientist, Immatics Biotechnologies Houston, TX
    • Austin Bigley PhD, Vice President, Research & Development, Indapta Therapeutics
    • Dara Missan, PhD, Mayo Clinic
    • Ignacio Nunez, MSc, Founder, BioExcellence, LLC